Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of AKCEA-APOCIII-LRx in familial chylomicronemia syndrome
NL-OMON52139Phase 3Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Aug 2021
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary chylomicronemia (FCS) comparing AKCEA-APOCIII-LRx with Placebo (2 arms). Primary endpoint: Percent change in fasting triglycerides from baseline at 6 months. Started Aug 2021; status: completed.
02
Drugs
olezarsen
03
Conditions
primary chylomicronemia (FCS)
Beyond the preview
Go deeper on NL-OMON52139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52139.